This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joel M. Gore, MD; James E. Dalen, MD

JAMA. 1991;265(23):3105-3107.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Although thrombolytic therapy has become the standard of care for patients with acute myocardial infarction, the number of patients who meet current eligibility criteria and actually receive thrombolytic therapy is small. Two studies^1,2 found that currently only 25% of all patients with infarct receive thrombolytic therapy. The principal reasons that the majority of patients with acute myocardial infarction do not receive thrombolytic therapy are age over 75 years, duration of symptoms more than 6 hours, or lack of diagnostic electrocardiographic (ECG) changes. It will be important to determine if the current "exclusions" are appropriate. The ISIS-3 study (Third International Study of Infarct Survival), a large international trial that has enrolled more than 50 000 patients, will help to answer some of these questions. This study, results of which are expected to be reported in summer 1991, includes patients treated with thrombolytic therapy up to 24 hours after the onset . . . [Full Text PDF of this Article]

Author Affiliations
University of Massachusetts Medical School,Worcester; University of Arizona College of Medicine, Tucson

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?